Value proposition

Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward.

Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

Immunogenicity Assessment & Protein Engineering, Cell Line Development to GMP Manufacturing, ADCs & GMP Bioconjugation, Custom Chemical Synthesis, Analytical and Bioassay Solutions, Linker Payloads, Pre-Formulation, Process Development, Technology Transfer, Integrated Drug Development and Manufacturing Programs, and Analytical Method Development